Dispatches > News
Spencer Platt/Getty Images

Court dismissal

Supreme Court | Despite few breakthroughs, embryonic stem cell research gets high court boost

Issue: "Roe v. Wade turns 40," Jan. 26, 2013

The U.S. Supreme Court dismissed a challenge to the Obama administration’s funding for embryonic stem cell research without comment on Jan. 7, allowing a circuit court’s ruling to stand upholding the research policy. Two adult stem cell researchers challenged the policy, arguing that it violates the Dickey-Wicker Amendment that forbids federal funding for projects that destroy embryos. Alliance Defending Freedom attorneys who argued on behalf of the two researchers said the success of adult stem cell research has made federally funded research on embryonic stem cells “irrelevant.” 

President George W. Bush authorized federal research on embryonic stem cells, but only for cell lines where embryos had already been destroyed. President Obama expanded that authorization in 2009, allowing federal research on embryonic stem cells as long as the embryos were already going to be discarded and the parents had consented to the destruction. Under the guidelines federal researchers are not supposed to be a part of the destruction of embryos.

The Alliance Defending Freedom attorneys argued that the guidelines gave incentive to destroy embryos, thus violating Dickey-Wicker. They also argued that the line between those destroying the embryos and the federal researchers using the destroyed embryos was fuzzy. But the D.C. Circuit Court and the Supreme Court rejected those arguments. 

We see you’ve been enjoying the content on our exclusive member website. Ready to get unlimited access to all of WORLD’s member content?
Get your risk-free, 30-Day FREE Trial Membership right now.
(Don’t worry. It only takes a sec—and you don’t have to give us payment information right now.)

Get your risk-free, 30-Day FREE Trial Membership right now.

Embryonic stem cells so far have produced few breakthroughs. In 2011, Geron Corp., one of the only companies doing experimental therapy derived from human embryonic stem cells, abruptly ended its program because of “capital scarcity and uncertain economic conditions.”

Emily Belz
Emily Belz

Emily, who has covered everything from political infighting to pet salons for The Indianapolis Star, The Hill, and the New York Daily News, reports for WORLD from New York City. Follow Emily on Twitter @emzleb.

Comments

You must be a WORLD member to post comments.

    Keep Reading

     

    Good credit

    Competency-based programs offer college credentials without the debilitating cost

     

    Soaring sounds

    Three recent albums highlight the aesthetic and emotional range…

     

    Numbers matter

    Understaffing the U.S. effort in Iraq from the beginning…

    Advertisement